AVTX
Avalo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.23
+1.21%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 59.0K | 59.0K | 441.0K | 1.9M | 18.1M |
| Cost of Revenue | 10.0M | — | (366.0K) | 1.3M | 3.4M |
| Gross Profit | (9.9M) | 59.0K | 807.0K | 640.0K | 14.6M |
| Operating Expenses | |||||
| R&D Expense | 64.4M | 50.1M | 52.1M | 13.8M | 31.3M |
| SG&A Expense | 27.0M | 22.9M | 17.2M | 10.3M | 20.7M |
| General & Admin Expense | 26.5M | 22.4M | 16.5M | 10.3M | 20.6M |
| Selling & Marketing Expense | 529.0K | 470.0K | 789.0K | 33.0K | 76.0K |
| Other Expenses | (10.0M) | — | — | 3.9M | 38.0K |
| Total Operating Expenses | 81.4M | 73.0M | 69.3M | 28.0M | 52.1M |
| Cost and Expenses | 91.4M | 73.0M | 69.0M | 29.3M | 55.5M |
| Operating Income (EBIT) | (91.4M) | (72.9M) | (68.5M) | (27.4M) | (37.4M) |
| Non-Operating | |||||
| Interest Income | 5.7M | 4.4M | 3.3M | — | — |
| Interest Expense | — | — | — | 3.4M | 4.2M |
| Net Interest Income | 5.7M | 4.4M | 3.3M | (3.4M) | (4.2M) |
| Other Non-Op Income/Expense | (8.8M) | (5.2M) | 33.5M | (4.2M) | (4.2M) |
| Non-Operating Income (excl Interest) | 8.8M | 5.2M | (33.5M) | (3.9M) | 20.0K |
| EBT (Pre-Tax Income) | (100.2M) | (78.1M) | (35.0M) | (31.5M) | (41.6M) |
| Income Tax Expense | 171.0K | 165.0K | 114.0K | 14.0K | 28.0K |
| Bottom Line | |||||
| Net Income | (100.3M) | (78.3M) | (35.1M) | (31.5M) | (41.7M) |
| Earnings from Cont. Ops | (100.3M) | (78.3M) | (35.1M) | (31.5M) | (41.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (100.3M) | (78.3M) | (35.1M) | (31.5M) | (41.7M) |
| Per Share | |||||
| Basic EPS | ($4.74) | ($5.84) | ($4.32) | ($113.58) | ($1,062.65) |
| Diluted EPS | ($4.74) | ($5.84) | ($3.26) | ($113.58) | ($1,062.65) |
| Revenue Per Share | $0.00 | $0.00 | $0.05 | $6.93 | $460.46 |
| Shares | |||||
| Basic Shares Outstanding | 43.6M | 13.4M | 8.1M | 277727 | 39202 |
| Diluted Shares Outstanding | 43.6M | 13.4M | 10.8M | 277727 | 39202 |
| Profitability Metrics | |||||
| EBITDA | (100.0M) | (77.8M) | (34.8M) | (23.3M) | (37.3M) |
| D&A | 126.0K | 344.0K | 169.0K | 158.0K | 166.0K |
| EBIT | (100.2M) | (78.1M) | (35.0M) | (23.4M) | (37.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026